High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 11, 2012, Pages 1677-1686

  Nieto, Yago ^a   Thall, Peter ^a   Valdez, Ben ^a   Andersson, Borje ^a   Popat, Uday ^a   Anderlini, Paolo ^a   Shpall, Elizabeth J ^a   Bassett, Roland ^a   Alousi, Amin ^a   Hosing, Chitra ^a   Kebriaei, Partow ^a   Qazilbash, Muzaffar ^a   Frazier, Erin ^a   Gulbis, Alison ^a   Chancoco, Christina ^a   Bashir, Qaiser ^a   Ciurea, Stefan ^a   Khouri, Issa ^a   Parmar, Simrit ^a   Shah, Nina ^a   Worth, Laura ^a   Rondon, Gabriela ^a   Champlin, Richard ^a   Jones, Roy B ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Autologous transplantation; Gemcitabine; High dose chemotherapy; Hodgkin; Lymphoma; Myeloma; Phase 1

Indexed keywords

ANTIBIOTIC AGENT; BRAIN NATRIURETIC PEPTIDE; BUSULFAN; C REACTIVE PROTEIN; FERRITIN; GEMCITABINE; HAPTOGLOBIN; MELPHALAN; METHYLPREDNISOLONE; STEROID; SUNSCREEN;

ADULT; AGED; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CARDIOTOXICITY; CELL PROLIFERATION; DERMATITIS; DIARRHEA; DISTRIBUTION VOLUME; DOSE CALCULATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; ERYTHEMA; EVENT FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; LARGE CELL LYMPHOMA; LOADING DRUG DOSE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; RASH; SIDE EFFECT; SKIN TOXICITY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA; MALE; MELPHALAN; MIDDLE AGED; MUCOSITIS; RECURRENCE; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84867514150     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.05.011     Document Type: Article

References (57)

1. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
2. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341:1051-1054.
3. Lazarus H.M., Loberiza F.R., Zhang M.J., et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 2001, 27:387-396.
4. Vose J.M., Zhang M.J., Rowlings P.A., et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001, 19:406-413.
5. Guglielmi C., Gomez F., Philip T., et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998, 16:3264-3269.
6. Hagberg H., Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomization to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006, 17(suppl 4):iv31-iv32. CORAL study group.
7. Caballero M.D., Pérez-Simón J.A., Iriondo A., et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003, 14:140-151.
8. Andersson B.S., Kashyap A., Gian V., et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002, 8:145-154.
9. Madden T., de Lima M., Thapar N., et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007, 13:56-64.
10. Kebriaei P., Madden T., Kazerooni R., et al. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant 2011, 17:412-420.
11. Carreras E., Rosiñol L., Terol M.J., et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007, 13:1448-1454.
12. Plunkett W., Huang P., Searcy C.E., Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996, 23(5 suppl 10):3-15.
13. Plunkett W., Huang P., Xu Y.Z., Heinemann V., Grunewald R., Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995, 22(4 suppl 11):3-10.
14. Hanauske A.R., Degen D., Marshall M.H., Hilsenbeck S.G., Grindey G.B., Von Hoff D.D. Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anticancer Drugs 1992, 3:143-146.
15. Csoka K., Liliemark J., Larsson R., Nygren P. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol 1995, 22(4 suppl 11):47-53.
16. Braakhuis B.J., Ruiz van Haperen V.W., Boven E., Veerman G., Peters G.J. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 1995, 22(4 suppl 11):42-46.
17. Bartlett N.L., Niedzwiecki D., Johnson J.L., et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007, 18:1071-1079.
18. Santoro A., Bredenfeld H., Devizzi L., et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000, 18:2615-2619.
19. Ng M., Waters J., Cunningham D., et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005, 92:1352-1357.
20. Crump M., Baetz T., Couban, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004, 101:1835-1842.
21. Grunewald R., Abbruzzese J.L., Tarassoff P., Plunkett W. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991, 27:258-262.
22. Grunewald R., Kantarjian H., Du M., Faucher K., Tarassoff P., Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992, 10:406-413.
23. Gandhi V., Plunkett W., Du M., Ayres M., Estey E.H. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 2002, 20:665-673.
24. Tempero M., Plunkett W., Ruiz Van Haperen V., et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003, 21:3402-3408.
25. Soo R.A., Wang L.Z., Tham L.S., et al. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 2006, 17:1128-1133.
26. Nieto Y., Aldaz A., Rifón J., et al. Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. Biol Blood Marrow Transplant 2007, 13:1324-1337.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
28. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007, 25:571-578.
29. O'Quigley J., Pepe M., Fisher L. Continual reassessment method: a practical design for phase I clinical trial in cancer. Biometrics 1990, 46:33-48.
30. National Cancer Institute. CTEP Cancer Therapy Evaluation Program. Available at: http://www.ctep.cancer.gov/protocoldevelopment/electronic./ctcaev3.pdf.
31. Thall P.F., Simon R.M., Estey E.H. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 1995, 14:357-379.
32. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
33. Rajkumar S.V., Harousseau J.L., Durie B., et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011, 117:4691-4695.
34. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Amer Statistical Assoc 1958, 53:457-481.
35. Spasokoukotskaja T., Arnér E.S., Brosjö O., et al. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer 1995, 31A:202-208.
36. Matsuda A., Sasaki T. Antitumor activity of sugar-modified cytosine nucleosides. Cancer Sci 2004, 95:105-111.
37. Shewach D.S., Ensminger W.D., Hughes T.L. Apparent substrate inhibition of deoxycytidine kinase. Proc Am Assoc Cancer Res 1994, 35:425. (abstract).
38. Bass A.J., Gockerman J.P., Hammett E., et al. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol 2002, 20:2995-3000.
39. Rizzieri D.A., Bass A.J., Rosner G.L., et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol 2002, 20:674-679.
40. Rizzieri D.A., Ibom V.K., Moore J.O., et al. Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. Clin Cancer Res 2003, 9:663-668.
41. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
42. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
43. Peters G.J., Ruiz van Haperen V.W., Bergman A.M., et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996, 23(5 suppl 10):16-24.
44. Valdez B.C., Murray D., Nieto Y., et al. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. Leuk Lymphoma 2012, 53:973-981.
45. Toy G., Austin W.R., Liao H.I., et al. Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci U S A 2010, 107:5551-5556.
46. Krett N.L., Ayres M., Nabhan C., et al. In vitro assessment of nucleoside analogs in multiple myeloma. Cancer Chemother Pharmacol 2004, 54:113-121.
47. Gruber J., Geisen F., Sgonc R., et al. 2'-2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA). Stem Cells 1996, 14:351-362.
48. Weick J.K., Crowley J.J., Hussein M.A., Moore D.F., Barlogie B. Southwest Oncology Group. The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study. Invest New Drugs 2002, 20:117-121.
49. Bieghs L., Caers J., De Bruyne E., et al. The effects of forodesine in murine and human multiple myeloma cells. Adv Hematol 2010, 2010:131895.
50. Brune V., Tiacci E., Pfeil I., et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 2008, 205:2251-2268.
51. Lenburg M.E., Sinha A., Faller D.V., Denis G.V. Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis. J Biol Chem 2007, 282:4803-4811.
52. Artz A.S., Wickrema A., Dinner S., et al. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:1209-1216.
53. Remberger M., Mattsson J. C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation. Int J Hematol 2010, 92:161-167.
54. Lim Z.Y., Fiaccadori V., Gandhi S., et al. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk Res 2010, 34:723-727.
55. Altes A., Remacha A.F., Sarda P., et al. Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol 2007, 86:443-447.
56. Matsubara J., Ono M., Negishi A., et al. Identification of a predictive biomarker for hematologic toxicities of gemcitabine. J Clin Oncol 2009, 27:2261-2268.
57. Kataoka K., Nannya Y., Iwata H., et al. Plasma brain natriuretic peptide is associated with hepatic veno-occlusive disease and early mortality after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2010, 45:1631-1637.